i2o
is a Massachusetts-based biotechnology company that researches and develops oral peptide and protein therapies for the treatment of cardiometabolic diseases... Read morei2o
is a Massachusetts-based biotechnology company that researches and develops oral peptide and protein therapies for the treatment of cardiometabolic diseases... Read more
News
Sep 24, 2023
Medthority
i2o: FDA advisory committee voted unanimously to reject an appeal for Intarcia Therapeutics' Type 2 diabetes drug-device combination treatment, citing continued safety concerns.
Sep 05, 2023
Drug Delivery Business
i2o: GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia
Jan 06, 2022
BioSpace
i2o Therapeutics: i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules
Feb 10, 2021
MarketScreener
i2o Therapeutics: i2O Therapeutics : Announces Research Collaboration with Sanofi to Enable Oral Delivery of Nanobody-based Medicines
Dec 07, 2020
Contract Pharma
i2o Therapeutics: Colorcon Ventures Invests in i20 Therapeutics
Dec 03, 2020
BioSpace
i2o Therapeutics: i2O Therapeutics Receives Strategic Investment from Colorcon Ventures and Enters into Research Collaboration with Colorcon
Apr 13, 2020
Techstartups
i2o Therapeutics: Harvard-launched biotech startup i2O Therapeutics launches to replace syringes with pills for oral delivery of many injectable drugs, including insulin
Apr 09, 2020
FierceBiotech
i2o Therapeutics: Harvard spins out biologics-in-a-pill company with a focus on Type 1 diabetes
